Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia
Information source: Population Health Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Defibrillators, Implantable; Tachycardia, Ventricular
Intervention: Ablation (Procedure); Amiodarone (Drug)
Phase: Phase 3
Sponsored by: Population Health Research Institute
Official(s) and/or principal investigator(s):
Andrea Natale, M.D., Principal Investigator, Affiliation: Texas Cardiac Arrhythmia Research Foundation
David J Callans, M.D., Principal Investigator, Affiliation: University of Pennsylvania
Carlos A. Morillo, M.D., Principal Investigator, Affiliation: Population Health Research Institute, McMaster University
Girish M. Nair, M.D., Principal Investigator, Affiliation: Population Health Research Institute, McMaster University
Implantable Cardioverter Defibrillators (ICDs) provide a shock or pacing therapy to bring
back a normal heart beat when a patient experiences a dangerous abnormal heart rhythm such
as ventricular tachycardia (VT). ICDs are very successful in bringing back a normal heart
beat when VT occurs, but they do not prevent further dangerous heart rhythms from occurring.
This study is designed to determine the best way to manage patients who have an ICD and who
continue to have episodes of VT. There are two methods for treatment the VT: 1) Ablation,
and 2) Medication.
An ablation procedure involves placing a flexible catheter (insulated wire) in the groin
area and threading it into the heart. After the doctor has located the affected area
responsible for the VT, radiofrequency energy is delivered by the power generator through
the catheter to the inside of the heart. The radiofrequency energy ablates (burns) a small
area of the heart tissue thought to cause the VT.
A medication called Amiodarone is an "anti-arrhythmic" prescribed to prevent abnormal heart
rhythms from recurring.
The purpose of this study is to compare these two different methods for treating VT.
Treatment with ablation and amiodarone are both considered the standard of care for patients
with VT but they have not been compared directly in a study like this before.
Official title: Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia: A Multi-center Randomized Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Composite outcome-time to first occurrence of any of: 1. Appropriate ICD Therapy 2. Slow VT below ICD detection threshold leading to hospitalization or necessitates antiarrhythmics and/or ablation 3. Sudden Cardiac Death
composite of: a. Ablation or amiodarone complications b. Inappropriate shocks from ICD c. Need for concomitant use of sotalol, dofetilide, azimilide or class I antiarrhythmic agents in either arm of the trial
Quality of life score in each treatment arm using the EQ-5D questionnaire
Minimum age: 19 Years.
Maximum age: 84 Years.
Inclusion Criteria - Patients must meet all of the following criteria:
- > 18 and < 85 years of age
- ICD implanted for primary prophylaxis against sudden cardiac death or ICD implanted
for secondary prophylaxis against spontaneous or inducible sustained VT without any
- CAD with prior MI
- ICD or ECG documentation of ventricular arrhythmia responsible for appropriate ICD
therapy [ATP & shocks].
Exclusion Criteria - Patients should not have any of the following criteria:
- Contraindication or allergy to contrast media, routine procedural medications or
- Contraindication to an interventional procedure
- Current or previous (within 3 months) amiodarone therapy
- Atrial Fibrillation requiring antiarrhythmic drug therapy
- Contraindication to amiodarone therapy
- New York Heart Association (NYHA) functional class IV
- Myocardial infarction within the past 60 days
- Stroke within the past 90 days
- Unstable angina
- Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic
Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT
or long QT syndrome
- Patients with active ischemia that are eligible for revascularization
- Life expectancy less than 6 months
- Incessant or multiple episodes of VT requiring immediate therapy with medications or
- Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid
hormone replacement therapy are acceptable.
- Current enrollment in another investigational drug or device study.
- Presence of any other condition that the investigator feels would be problematic or
would restrict or limit the participation of the patient for the entire study period.
- Absolute contra-indication to the use of heparin and or warfarin.
- Documented intra-atrial thrombus, ventricular thrombus (< 6 months after detection of
thrombus), tumor, or another abnormality which precludes catheter introduction.
- Females of childbearing potential who are not practicing protocol acceptable method
of birth control.
Locations and Contacts
Institut Universitaire de Cardiologie et Pneumologie de Québec, Quebec G1V 4G5, Canada
Beijng Fuwai Heart Hospital, Beijing 100037, China
Northwestern University, Chicago, Illinois 60611, United States
Mayo Clinic, Rochester, Minnesota 55905, United States
Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada
Southlake Regional Health Centre, Newmarket, Ontario L3Y 2P9, Canada
University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
McGill University Health Center, Montreal, Quebec H3G 1A4, Canada
Texas Cardiac Arrhythmia Research Foundation, Austin, Texas 78705, United States
University of Virginia Health System, Charlottesville, Virginia 22908, United States
Population Health Research Institute
Starting date: August 2010
Last updated: August 4, 2011